Michael W Schuster MD

Oncology•New York, NY

Hematologic Oncology

Professor of Hematology & Oncology, SUNY Stony Brook

Join to View Full Profile

520 E 70th St# StarrNew York, NY 10021
Phone+1 212-746-2119
Fax+1 212-746-3305

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1987
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1980 - 1983
Geisel School of Medicine at DartmouthClass of 1980

Certifications & Licensure

CA State Medical License 1981 - Present
MA State Medical License 1982 - 2027
NY State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Newsday - Top Doctors on Long Island Castle Connolly, 2011-2020
America's Top Doctors for Cancer Castle Connolly, 2005-2020
Top Doctors: New York Metro Area Castle Connolly, 2003-2014, 2016-2020
America's Top Doctors Castle Connolly, 2002-2014, 2017-2020
New York Magazine: Top Doctors Castle Connolly, 2002-2014, 2016-2019
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients Start of enrollment: 2010 Jun 01
Terminated
Phase 2
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Completed
Phase 4
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease Start of enrollment: 2012 Oct 01
Completed
Phase 2
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients Start of enrollment: 2015 Feb 01
Completed
Phase 2
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2023 Jan 26
COMPLETED
PHASE1, PHASE2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Randomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2025-01-10
4 citations
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients.
Sanjeet S Dadwal, Rajat Bansal, Michael W Schuster, Jean A Yared, Gary Douglas Myers
Blood Advances. 2024-09-10
An MDS Patient with Deletion 20q and a t(9;22)(q34;q11.2): A Case Report and Review of the Literature.
Sam Roush, Tahmeena Ahmed, Michael Schuster, Kevin Wang, Elizabeth Lee
Journal of the Association of Genetic Technologists. 2024-01-01

Abstracts/Posters

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Mye...
Michael W. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid LeukemiaClinically Relevant Abstract
Michael W. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member